ACTIVE

Surveal Pharma

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result431,2 k €+155,2 %over 1 year

Gross margin757 k €+59,2 %over 1 year

Equity1,8 M €+31,1 %over 1 year

Workforce0,1 ETP

Identity

Source · BCE/KBO

Surveal Pharma is a Private limited company incorporated in 2011. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Ixelles. It employs on average 0,1 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0837.880.555
Incorporation: 12/07/2011
Legal form: Private limited company
Registered office: Avenue Louise 143 box 4
1050 Ixelles · BruxellesSee on map
Contributed capital: 50 000,00 €
Latest accounts: 31/12/2025
Average workforce: 0,1 ETP

Activities (NACE)

46460Wholesale of pharmaceutical goods· main 46460Wholesale of pharmaceutical goods 21100Manufacture of basic pharmaceutical products 21100Manufacture of basic pharmaceutical products 21201Manufacture of pharmaceutical preparations 21201Manufacture of pharmaceutical preparations+2

Joint committees (1)

2070

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 14 filings

Trend over 13 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	757 k €	+59.2%	475,5 k €	-41.0%	805,5 k €	+60.8%	501,1 k €	-33.6%	754,5 k €
EBITDA	724 k €	+57.5%	459,6 k €	-41.4%	784,2 k €	+67.1%	469,4 k €	-35.3%	725,4 k €
Operating result	685,5 k €	+70.9%	401,1 k €	-44.8%	727,2 k €	+71.4%	424,3 k €	-37.8%	682,1 k €
Net result	431,2 k €	+155%	-780,4 k €	-244%	542,4 k €	+90.1%	285,3 k €	-30.9%	412,9 k €
Balance sheet
Equity	1,8 M €	+31.1%	1,4 M €	-36.0%	2,2 M €	+33.4%	1,6 M €	+21.3%	1,3 M €
Total assets	5,5 M €	-7.6%	5,9 M €	-25.5%	7,9 M €	+15.3%	6,9 M €	+14.3%	6 M €
Cash	1,4 M €	-46.8%	2,7 M €	+26.6%	2,1 M €	-24.7%	2,9 M €	+190%	983,4 k €
Debts	3,6 M €	-19.4%	4,5 M €	-21.6%	5,8 M €	+9.7%	5,3 M €	+12.4%	4,7 M €
Other
Workforce	0,1 ETP		0,0 ETP	-100%	0,1 ETP		–		–

Valuation

Indicative valuation

As an indication, this company is worth

between 2,5 M€ and 5 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 7 ended

Active mandates

Sam Khoury

Director · since 31 mai 2018

Active

Ended mandates

OUSSAMA KHOURY

Director · since 01 janvier 2020

Ended

Oussama Khoury

Director · since 31 mai 2018

Ended

Oussama KHOURY

Manager · since 12 juillet 2011

Ended

Roy Moukheiber

Manager · since 12 juillet 2011

Ended

Other companies at this address

Avenue Louise 143 1050 Ixelles

Company	CBE no.
5SENSES● Active	0716.899.878
AAKN Trans● Bankrupt	0427.924.111
ABC LIFT● Bankrupt	0642.540.371
Absolute Focus● Active	0646.874.984
ACCETRANS● Active	0469.296.688
ACCURIS● Active	0505.815.408
AD MANAGEMENT SRL● Active	0801.295.521
AEROCARE● Active	0880.285.886
AHM GROUP● Bankrupt	0646.672.274
Alain afflelou belgique● Active	0885.723.232
ALEPHSYS● Active	0832.001.365
ALF BUILD● Active	0798.908.925
Alixio Benelux● Active	0792.187.617
ALREC GROUP● Active	0751.693.283
Alyzia Belgium● Active	0749.517.020
APPARTIMMO● Active	0436.842.864
ARKEMA ANTWERP● Active	0460.850.166
AR Law & Tax● Active	1024.457.778
ARS CONSULT● Active	0874.904.663
Arvida Investments● Active	0465.389.964

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	31/08/2026	27/08/2025	10/12/2024	05/01/2024	26/09/2022	30/09/2021
General meeting	30/06/2026	30/06/2025	14/11/2024	26/12/2023	22/09/2022	30/09/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 14 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	30/06/2026	31/08/2026	French	PDF
Abridged model	31/12/2024	30/06/2025	27/08/2025	French	PDF
Abridged model	31/12/2023	14/11/2024	10/12/2024	French	PDF
Abridged model	31/12/2022	26/12/2023	05/01/2024	French	PDF
Abridged model	31/12/2021	22/09/2022	26/09/2022	French	PDF
Abridged model	31/12/2020	30/09/2021	30/09/2021	French	PDF
Abridged model	31/12/2019	31/05/2020	09/10/2020	French	PDF
Abridged model	31/12/2018	31/05/2019	07/11/2019	French	PDF
Abridged model	31/12/2017	31/05/2018	28/09/2018	French	PDF
Abridged model	31/12/2016	31/05/2017	04/01/2018	French	PDF
Abridged model	31/12/2015	31/05/2016	22/12/2016	French	PDF
Abridged model	31/12/2014	31/05/2015	12/02/2016	French	PDF
Abridged model	31/12/2013	31/05/2014	30/12/2014	French	PDF
Abridged model	31/12/2012	31/05/2013	30/08/2013	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 2,5 M€ and 5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 7 ended

Active mandates

Sam Khoury

Director · since 31 mai 2018

Active

Ended mandates

OUSSAMA KHOURY

Director · since 01 janvier 2020

Ended

Oussama Khoury

Director · since 31 mai 2018

Ended

Oussama KHOURY

Manager · since 12 juillet 2011

Ended

Roy Moukheiber

Manager · since 12 juillet 2011

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates07/02/2022
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - MODIFICATION FORME JURIDIQUE - DENOMINATION - DIVERS - DEMISSIONS, NOMINATIONS
PDF
Mandates24/08/2020
SIEGE SOCIAL - ADRESSE AUTRE QUE SIEGE SOCIAL - DEMISSIONS, NOMINATIONS - MODIFICATION FORME JURIDIQUE
PDF
Mandates03/07/2018
DEMISSIONS, NOMINATIONS
PDF
Capital / shares07/02/2014
CAPITAL, ACTIONS - STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF
Other27/07/2011
RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

2025
Annual accounts 2025431,2 k €↑
2024
Annual accounts 2024-780,4 k €↓
2023
Annual accounts 2023542,4 k €↑
2022
Annual accounts 2022285,3 k €↓
2021
Annual accounts 2021412,9 k €↑
2019
Annual accounts 201973,1 k €↓
2018
Annual accounts 2018105,8 k €↑
2017
Annual accounts 201799,7 k €↑
2016
Annual accounts 201630,4 k €↓
2015
Annual accounts 201535,9 k €↓
2014
Annual accounts 201461,6 k €↓
2013
Annual accounts 2013351,2 k €↑
2012
Annual accounts 2012-183,9 k €
12/07/2011
IncorporationPrivate limited company

Surveal Pharma

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline